Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma.
Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma.
复制标题
氟尿嘧啶和重组α-2a-干扰素：针对晚期结直肠癌的积极疗法。
DOI：
--
复制
发表时间：
1989
影响因子：
45.3
通讯作者：
P. Wiernik
中科院分区：
文献类型：
--
作者：
S. Wadler;E. Schwartz;M. Goldman;A. Lyver;M. Rader;M. Zimmerman;L. Itri;V. Weinberg;P. Wiernik
基于已经证明重组α-2a-干扰素（rIFN α-2a）和氟尿嘧啶（5 FU）之间针对两种人结肠癌细胞系的协同作用的体外研究，启动了初步临床试验以确定5 FU和rIFN α-2a的组合在患有晚期不可切除的结肠直肠癌的患者中的作用。共入组30例患者;所有患者均可评价。5 FU负荷治疗，750 mg/m2/d，连续5 d，每周1次，rIFN α-2a 9 MU皮下注射，每周3次。在17例可评价缓解的既往未治疗患者中，13例达到缓解。3例患者出现疾病进展。既往接受过治疗的患者均未出现重大缓解。有1例死亡明显与治疗相关，该事件发生在水样腹泻和贫血性脓毒症之前。其他毒性是可逆的，对剂量降低有反应。中位随访时间为16个月以上，此前未经治疗的患者队列尚未达到中位生存期。我们的结论是，5 FU和rIFN α-2a的组合是一个积极的方案，对以前未经治疗的患者播散性结直肠癌。
Based on in vitro studies that have demonstrated synergy between recombinant alfa-2a-interferon (rIFN alpha-2a) and the fluoropyrimidine, fluorouracil (5FU), against two human colon cancer cell lines, a pilot clinical trial was initiated to determine the effects of the combination of 5FU and rIFN alpha-2a in patients with advanced, unresectable colorectal carcinoma. A total of 30 patients were enrolled; all were evaluable. 5FU was administered as a loading course, 750 mg/m2 daily for 5 days by continuous infusion followed by weekly bolus therapy, rIFN alpha-2a, 9 MU, was administered subcutaneously three times per week. Of 17 previously untreated patients evaluable for response, 13 achieved a response. Three patients had disease progression. No previously treated patients had a major response. There was one death clearly related to therapy, an event preceded by watery diarrhea and neutropenic sepsis. Other toxicities were reversible and responded to dose reduction. With a median follow-up of 16+ months, median survival has not been reached among the previously untreated patient cohort. We conclude that the combination of 5FU and rIFN alpha-2a is an active regimen against disseminated colorectal cancer in previously untreated patients.